BACKGROUND The Spanish HIV HGM BioBank is of great relevance for basic and clinical investigation, and for those groups trying to establish large networks focused on investigation on specific clinical problems. The collection of different types of samples from HIV-infected individuals is the beginning of the chain of translational investigation, starting in 2004 a prospective national HIV BioBank that expanded in 2009 a local node (HGM: Hospital Gregorio Marañón) for diverse pathologies and clinical networks, not only in adults but also in paediatric patients, becoming the Spanish HIV HGM BioBank. Our main objective is to find a general criteria and analytical tools to widespread its economic management to assure their sustainability and the future exploitation of the extreme high valuable biomaterial they custody. METHODS The Spanish HIV HGM BioBank was created with the aim of contributing to advance understanding of different pathologies through the transfer, management, register, processing, cryopreservation and cession of biological material from patients, always for research purposes and under conditions that guarantee its usefulness in current studies and future research that may appear as knowledge evolves. In this study, we have developed a policy for financial control and recovery costs of the Spanish HIV HGM BioBank. RESULTS Actually, Spanish HIV HGM BioBank guards 413,747 vials of 46,594 samples from 16,210 donors with various prospective longitudinal study type of samples. Interestingly, more than 7907 of these samples are now used in 28 national and international investigation projects and clinical trials. One of the objectives of this study is to develop an economic plan that you get future projects, design of acceptance or rejection keys, have internal investment limits, minimum recovery needs in short/medium term, deviation detection system and a register of capital recovery by period and type of service for the Spanish HIV HGM BioBank. CONCLUSION Our model can help BioBanks that do not have a costs recovery model to design it, as well as to detect improves and functional revisions to those experienced in this field.

中文翻译：

---

评估和衡量西班牙 HIV HGM 生物银行的财务可持续性模型。

背景 西班牙 HIV HGM 生物库对于基础和临床研究以及那些试图建立专注于特定临床问题研究的大型网络的团体具有重要意义。从 HIV 感染者收集不同类型的样本是转化调查链的开始，从 2004 年开始，一个前瞻性的国家 HIV 生物库于 2009 年扩展了一个本地节点（HGM：Hospital Gregorio Marañón），用于各种病理和临床网络，不仅在成人中，而且在儿科患者中，成为西班牙 HIV HGM 生物库。我们的主要目标是找到一个通用的标准和分析工具来推广其经济管理，以确保他们的可持续性和未来对他们所持有的极高价值生物材料的利用。方法 西班牙 HIV HGM 生物库的创建旨在通过转移、管理、登记、处理、冷冻保存和转让来自患者的生物材料，促进对不同病理的了解，始终用于研究目的，并在保证其在随着知识的发展，可能出现的当前研究和未来研究。在这项研究中，我们制定了西班牙 HIV HGM 生物库的财务控制和回收成本政策。结果 实际上，西班牙 HIV HGM 生物库保护了来自 16,210 名捐赠者的 413,747 瓶 46,594 个样本，这些样本具有各种前瞻性纵向研究类型。有趣的是，这些样本中有超过 7907 个现在用于 28 个国家和国际调查项目和临床试验。本研究的目标之一是制定一个经济计划，让您获得未来项目、接受或拒绝密钥的设计、内部投资限制、短期/中期的最低回收需求、偏差检测系统和资本回收登记册西班牙 HIV HGM 生物库的服务期限和类型。结论 我们的模型可以帮助没有成本回收模型的生物银行设计它，以及检测对该领域经验的改进和功能修订。